A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)

Recruiting

Phase 2

TebapivatA Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)

Sponsor:

Agios Pharmaceuticals, Inc.

Code:

NCT06924970

Conditions

Sickle Cell Disease

Eligibility Criteria

Sex: All

Age: 16+

Healthy Volunteers: Not accepted

Interventions

Tebapivat

Tebapivat Matched Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-01-02. This information was provided to ClinicalTrials.gov by Agios Pharmaceuticals, Inc. on 2025-12-03.